V
Vinod Pullarkat
Researcher at City of Hope National Medical Center
Publications - 280
Citations - 9132
Vinod Pullarkat is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 37, co-authored 219 publications receiving 6536 citations. Previous affiliations of Vinod Pullarkat include University of Southern California & Biogen Idec.
Papers
More filters
Journal ArticleDOI
Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider
Dominik Selleslag,Robert Bird,Ivy Altomare,Aristoteles Giagounidis,Ann Janssens,Ingrid Pabinger,Vinod Pullarkat,Helen Wei,Georg Kreuzbauer +8 more
TL;DR: This post hoc analysis evaluated romiplostim self‐administration (SA group) vs. romiplOSTim administration by a healthcare provider in a clinical setting (HCP group) in patients with chronic immune thrombocytopenia (ITP).
Journal ArticleDOI
Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.
Keith W. Pratz,Brian A. Jonas,Vinod Pullarkat,Christian Recher,Andre C. Schuh,Michael J. Thirman,Jacqueline S. Garcia,Courtney D. DiNardo,Vladimir I. Vorobyev,Nicola Stefano Fracchiolla,Su-Peng Yeh,Jun Ho Jang,Muhit Ozcan,Kazuhito Yamamoto,Árpád Illés,Ying Zhou,Monique Dail,Brenda Chyla,Jalaja Potluri,Hartmut Döhner +19 more
TL;DR: It is shown that in the phase 3 VIALE-A trial, rates of composite complete remission (CRc; complete remission [CR] + CR with incomplete hematologic recovery [CRi]) and measurable residual disease re...
Journal ArticleDOI
Phase 2 study of suberoylanilide hydroxamic acid (SAHA) in relapsed or refractory indolent non-Hodgkin lymphoma: A California Cancer Consortium study
Mark Kirschbaum,Jasmine Zain,Leslie Popplewell,Vinod Pullarkat,N. Obadike,Paul Frankel,J. Zwiebel,S.J. Forman,Edward M. Newman,David R. Gandara +9 more
TL;DR: In this paper, the indolent (follicular, marginal zone and mantle cell) lymphomas tend to recur with decreasing intervals of remission post standard chemotherapy using Vorinostat (SAHA, Zolinza).
Journal ArticleDOI
Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with NUP214-ABL1.
Ibrahim Aldoss,Vinod Pullarkat +1 more
TL;DR: This is a 26-year-old Latino female with B-cell ALL who underwent allogeneic hematopoietic cell transplantation (alloHCT) following total body irradiation and etoposide conditioning from her HLA-matched brother and remains on dasatinib at 140mg daily.
Journal ArticleDOI
Therapy-related acute lymphoblastic leukemia: Where do we stand with regards to its definition and characterization?
TL;DR: All related to prior cytotoxic therapy (t-ALL) appears to be a distinct entity when compared to the de novo ALL, with characteristics including older age at the time of onset, female predominance and leukemia genetics enriched with KMT2A (MLL) gene rearrangement and chromosomes 5/7 abnormalities.